Videos 2025
ESC Congress 2025 DANFLU-2/DAN-RSV
Prof. Tor Biering-Sørensen on prevention through vaccinations: DANFLU-2 and DAN-RSV presented at the ESC Congress in Madrid 2025.
Videos 2024
NUDGE-FLU study
Dr. Harriette Van Spall speaks with Tor Biering-Sørensen about the NUDGE-FLU study, which investigates how electronic ‘nudges’ can increase influenza vaccination rates in patients with a history of myocardial infarction.
Videos on DANFLU-1 and DANFLU-2
DANFLU-2: Final phase of the DANFLU study launched
Tor Biering-Sørensen is interviewed about the DANFLU-2 study, featured on the TV2 Kosmopol news broadcast. (Watch from 09:03).
DANFLU-2: Participation
Tor Biering-Sørensen presents the DANFLU-2 study and describes the participants’ involvement.
DANFLU-1: Secondary analysis
In this video, Khurram Nasir, MBBS, FACC, JACC Associate Editor, and Tor Biering-Sørensen, MD, MPH, PhD, discuss the importance of influenza vaccination in patients with chronic kidney disease (CKD). They review the results of the DANFLU-1 study, which compared high-dose and standard-dose influenza vaccines, and look ahead to the DANFLU-2 study, expected to provide more definitive answers. The discussion also highlights the broader benefits of influenza vaccination, including the reduction of cardiovascular and renal complications in high-risk patients. The study is published in JACC, and the video relates to findings presented at the ESC Congress in London 2024.
Videos 2022
DANFLU-1: High-dose vs. standard-dose influenza vaccines in adults aged 65–79 years
Tor Biering-Sørensen speaks with Aaysha Cader about the results of the DANFLU-1 study, presented at the ESC Congress 2022 in Barcelona. The findings showed that older adults who received a high-dose influenza vaccine, compared with a standard-dose, experienced a significantly reduced risk of death and hospitalization from influenza or pneumonia.
DANFLU-1: CardioInfo - ESC 2022
In this video, Tor Biering-Sørensen comments on the results of DANFLU-1, presented at the ESC Congress 2022.
DANFLU-1: Results
In this video, Tor Biering-Sørensen summarizes the results of the DANFLU-1 study. The study tested the possibility of embedding an individually randomized trial into routine influenza vaccination practice and using Danish health registries to collect baseline, outcome, and safety data for standard- and high-dose vaccines in older adults.
DANFLU-1: Meet the trialist ESC 2022
In this video, we meet the researchers behind the DANFLU-1 study, Tor Biering-Sørensen and Niklas Dyrby Johansen, MD and PhD student. They were interviewed on the main stage at the ESC Congress 2022 in Barcelona by Ole Frobert, professor and cardiologist at Örebro University Hospital. Hear them discuss the DANFLU-1 study and its findings.
DANFLU-1: ESC TV 2022
Interview with Tor Biering-Sørensen, in which he briefly discusses the results of DANFLU-1.
Video 2019
Tor Biering-Sørensen is researching markers for future heart disease. The research is funded by the Lundbeck Foundation.
In this video, you can hear Tor Biering-Sørensen explain how heart disease can be prevented by offering preventive treatment to older adults at high risk of developing cardiovascular conditions. The research is supported by the Lundbeck Foundation Fellowship program. You can also read an interview with Tor Biering-Sørensen on the Lundbeck Foundation’s website.
The page is updated continuously.